Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :27
Small font sizeDefault font sizeIncrease font size
Navigate here
  Search
 
 » Next article
 » Previous article 
 » Table of Contents
  
Resource links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (696 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)  

 
  In this article
 »  References
 »  Article Figures

 Article Access Statistics
    Viewed3090    
    Printed94    
    Emailed3    
    PDF Downloaded228    
    Comments [Add]    
    Cited by others 5    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2009  |  Volume : 46  |  Issue : 4  |  Page : 352-354
 

Primary neuroendocrine carcinoma of the breast, which chemotherapy?


1 Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco
2 Department of Pathology, National Institute of Oncology, Rabat, Morocco

Date of Web Publication9-Sep-2009

Correspondence Address:
L K El Hassani
Department of Medical Oncology, National Institute of Oncology, Rabat
Morocco
Login to access the Email id


DOI: 10.4103/0019-509X.55566

PMID: 19749475

Get Permissions



How to cite this article:
El Hassani L K, Bensouda Y, M'Rabti H, Boutayeb S, Kamouni M, Gamra L, Errihani H. Primary neuroendocrine carcinoma of the breast, which chemotherapy?. Indian J Cancer 2009;46:352-4

How to cite this URL:
El Hassani L K, Bensouda Y, M'Rabti H, Boutayeb S, Kamouni M, Gamra L, Errihani H. Primary neuroendocrine carcinoma of the breast, which chemotherapy?. Indian J Cancer [serial online] 2009 [cited 2014 Apr 18];46:352-4. Available from: http://www.indianjcancer.com/text.asp?2009/46/4/352/55566


Sir,

Primary neuroendocrine carcinomas of the breast are extremely uncommon, with only very few cases published in English literature. Their best treatment is still unknown and various modes of management have been employed in treating this disease.

A 40-year-old woman presented with a lump in her right breast with pain and rapidly progressing tender, firm, enlarged breast [Figure 1]. Mammography revealed an irregular bulky mass of 10 cm. A biopsy was performed, and neuroendocrine carcinoma was diagnosed by histological examination. Immunohistochemistry was positive for neuron specific enolase [Figure 2], synaptophysine and chromogranine. While the progesterone receptor was positive in more than 50%, the oestrogen receptor was negative. The radiological investigations (Computed tomography (CT) scan of the chest, abdominal CT scan, brain CT scan, and bone scintigraphy) were negative for both metastatic and other primary diseases. The evaluation after three cycles of FAC (5 fluorouracil, adriamycin, cyclophospahmide) showed progression [Figure 3] with the development of cerebral metastasis. She died after one cycle of VP16-CDDP.

Neuroendocrine tumors of the breast are a rare malignancy in general, their prevalence is about 0.5% in a series of 1368 histopathologically proven breast cancers. [1]

Their clinical and imaging features mimic those of breast carcinomas in many ways without any specificity. [2] Our patient had an irregular lump of 10/15 cm, with erythematous and oedematous skin, and its mammography revealed an irregular bulky mass.

To diagnose a primary neuroendocrine carcinoma of the breast, a nonmammary site has to be excluded clinically and / or an in situ component should be demonstrated histologically. The imaging procedures required to exclude other primary tumors or distant metastases are: chest, abdominal and pelvic CT scan, bone scan, and positron emission tomography (PET) scanning. [3] All these radiological investigations were carried out in our case except PET scanning.

Most patients are treated as for adenocarcinoma of the breast. [4] The majority of information that guides management consists of retrospective chart reviews, anecdotal experience, and case reports. However, it seems acceptable that the initial management of patients with localized neuroendocrine tumor disease should be similar to the treatment of the other tumor types arising in the same site, with the exception of pulmonary neuroendocrine tumors. [4]

Regarding systemic management, there is no standard treatment protocol and a large variety of chemotherapy protocols have been employed in treating this disease. Systemic therapy principles have been derived from small retrospective case reviews of primary neuroendocrine breast carcinomas and extrapolated from studies of nonbreast neuroendocrine carcinomas, since the clinical behavior and histology are similar.

All data suggest that chemotherapy should be similar to their pulmonary counterpart and the most used chemotherapeutic regimen is VP16-CDDP. [5] Our patient was treated as for adenocarcinoma of the breast; she received FAC as neoadjuvant chemotherapy. Anthracyclines were ineffective in our case, and VP16-CDDP was probably the most appropriate regimen in this situation.

 
 » References Top

1.López-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernadó L, Menendez JA. Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep. 2008;20:1369-74  Back to cited text no. 1    
2.Fujimoto Y, Yagyu R, Murase K, Kawajiri H, Ohtani H, Arimoto Y, Yamamura T, et al . A case of solid neuroendocrine carcinoma of the breast in a 40 year old woman. Breast Cancer 2007;14: 250-3.   Back to cited text no. 2    
3.Rosen PP. Rosen's breast pathology. 2 nd ed. Lippincott: Williams and Wilkins; 2001 . p. 503-8.   Back to cited text no. 3    
4.Jochems L, Tjalma WA. Primary small cell neuroendocrine tumour of the breast. Eur J Obstet Gynecol Reprod Biol 2004; 115: 231-3.  Back to cited text no. 4    
5.Sridar P, Matey P, Aluwihare N. Primary carcinoma of breast with small-cell differentiation. Breast 2004;13: 149-51.  Back to cited text no. 5    


    Figures

  [Figure 1], [Figure 2], [Figure 3]

This article has been cited by
1 Neuroendocrine breast tumours: Breast cancer or neuroendocrine cancer presenting in the breast?
R.W. Adams,P. Dyson,L. Barthelmes
The Breast. 2013;
[Pubmed]
2 Primary neuroendocrine carcinoma of the breast
Rehman, A.
Journal of the College of Physicians and Surgeons Pakistan. 2013; 23(4): 282-284
[Pubmed]
3 Primary neuroendocrine breast carcinoma
Menéndez, P. and García, E. and Rabadán, L. and Pardo, R. and Padilla, D. and Villarejo, P.
Clinical Breast Cancer. 2012; 12(4): 300-303
[Pubmed]
4 Primary Neuroendocrine Breast Carcinoma
Pablo Menéndez,Esther García,Lorenzo Rabadán,Ricardo Pardo,David Padilla,Pedro Villarejo
Clinical Breast Cancer. 2012; 12(4): 300
[Pubmed]
5 Neuroendocrine carcinoma of the breast, diagnosis and therapy analysis
Geng, F.-Y. and Shi, X.-X. and Lu, S.-Q. and Li, M. and Yang, Z.-F. and Wang, W.-Z. and Wen, Y.-M.
Journal of Dalian Medical University. 2010; 32(4): 447-449
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Medknow